In one paragraphArticle in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Molood BehbahanipourInstitut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), 08193, Spain.ORCID https://orcid.org/0000-0002-7889-6105 Carla GoldinCentro de Rediseño e Ingeniería de Proteínas (CRIP), Instituto de Investigaciones Biotecnológicas (IIB), Universidad Nacional de San Martín (UNSAM), Buenos Aires, B1650, Argentina.ORCID https://orcid.org/0000-0001-8996-4153 Oriol BárcenasInstitut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), 08193, Spain.ORCID https://orcid.org/0000-0002-8439-4005 Susanna NavarroInstitut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), 08193, Spain.ORCID https://orcid.org/0000-0001-8160-9536 Jordi PujolsInstitut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), 08193, Spain.ORCID https://orcid.org/0000-0001-9424-5866 Daniel H MurgidaDepartamento de Química Inorgánica, Analítica y Química Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, C1428, Argentina.
Sebastián EsperanteCentro de Rediseño e Ingeniería de Proteínas (CRIP), Instituto de Investigaciones Biotecnológicas (IIB), Universidad Nacional de San Martín (UNSAM), Buenos Aires, B1650, Argentina.ORCID https://orcid.org/0000-0002-5778-6871 Damian Alvarez-PaggiCentro de Rediseño e Ingeniería de Proteínas (CRIP), Instituto de Investigaciones Biotecnológicas (IIB), Universidad Nacional de San Martín (UNSAM), Buenos Aires, B1650, Argentina.ORCID https://orcid.org/0000-0002-1507-9685 Salvador VenturaInstitut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), 08193, Spain.ORCID https://orcid.org/0000-0002-9652-6351 Funding
Agencia I+D+i, Argentina PICT 2020 SERIE A 00067Agencia I+D+i, Argentina PICTA A CAT I 00008Agencia I+D+i, Argentina PICTO-COVID-INMUNIZACION-0004Ministerio de Ciencia e Innovación FPU22/03656Ministerio de Ciencia e Innovación PID2022-137963OB-I00Ministerio de Ciencia e Innovación PRE2020-092634Spanish Ministry of Science and Innovation FPU22/03656Spanish Ministry of Science and Innovation PID2022-137963OB-I00
6 · The paper itselfAbstract
The ongoing threat of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the limitations of conventional antibody-based therapeutics (ABTs) underscore the need for scalable and customizable antiviral platforms. A modular, protein-only nanoscaffold based on recombinant ring-like particles (RLPs) derived from a viral nucleoprotein (NP), engineered is presented to display high-affinity, de novo-designed minibinders (LCB1 and LCB3) targeting SARS-CoV-2 Spike (S)protein. These binders are site-specifically fused to either the N- or C-termini, or both ends of NP to ensure functional orientation and dense, multivalent display. The resulting constructs self-assemble into stable, biocompatible, and homogeneous nanoparticles that potently inhibit S-angiotensin-converting enzyme 2 receptor (ACE2r) interactions, neutralizing both pseudotyped viral-like particles and authentic SARS-CoV-2, including Omicron BA.5. The dual-display nanoparticle (RLP-1,3), presenting 10 LCB1 and 10 LCB3 domains, exhibit synergistic binding activity, with fM Half Maximal Inhibitory Concentration(IC
Indexed as
Antibodies, NeutralizingNanoparticlesSARS-CoV-2Angiotensin-Converting Enzyme 2Antibodies, ViralCOVID-19HumansSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2minibindersprotein scaffoldSARS‐CoV‐2therapeuticviral neutralization
Identifiers
PMID41047514
PMCPMC12988574
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390